The Latest in Intellectual Property News

Early indications are that SMEs are embracing the Unitary Patent System and the benefits it offers in terms of cost, simplicity and the...

Working in Life Sciences, where the business model for innovators tends to favour exclusivity, the world of Standard Setting...

Some great presentations and discussions at yesterday’s ‘Unleashing the Potential of AI’ International Technology Conference. Thanks to...

As every European patent attorney knows, the Unified Patent Court (UPC) comes into force today (1st June 2023) effectively launching the...

Looking for help developing your IP Strategy? UK Start Ups and SMEs can benefit from £2,500 funding towards an IP Audit which is...

It’s the start of the year and there's so much to plan, do and deliver. Your IP portfolio is your most important asset but are you...

Excited for my in-person conference! Join me at London IP Week on 19th-21st September for a discussion that I'm speaking about on "Mr...

Scientist or engineer with an innovative idea for a new product or service; have you taken the time to secure your IP rights? Well down...

CEO, CSO or leader of a tech-based Start-Up or SME? Thought about your IP strategy of late and how you plan to implement it? Maybe your...

Are you a commercial lawyer, tech transfer professional or contracts manager dealing with IP agreements? Using your company’s boilerplate...

Leading role in a tech-based Start Up or SME? At the start of the year, why not take some time out to review your IP strategy and how you...

Whether you’re wanting to know if your invention is novel, check out a competitor’s activities, perform an IP landscape analysis, or...

As patent attorneys and IP lawyers, we have a tendency to get bogged down in the legal intricacies and issues surrounding new inventions...

Last week, I really enjoyed attending International IP Law Association’s Virtual IP Summit, particularly the sessions on IP strategy,...

As previously reported, in December last year a Californian court held that Gilead Sciences’ Kite Pharma’s sales of its blood cancer...

While the past year has been eventful in the CRISPR/Cas9 patent dispute, the question still remains as to whether the Broad Institute or...

On Friday 13th December 2019 a Californian court ruled against Kite Pharma, holding that its blood cancer therapy Yescarta infringed Juno...

In September 2018 the US Federal Court of Appeal upheld a lower court’s decision in favour of the Broad Institute, finding that Broad’s...